Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The aim of this study was to evaluate the dose-dependent effect of dulaglutide, a glucagon-like peptide-1 receptor agonist, on glycaemic control in Japanese patients with type 2 diabetes mellitus who were treated with diet/exercise or oral antidiabetic drug monotherapy. In this randomised, double-blind, placebo-controlled, parallel-group, 12-week study, patients received once weekly subcutaneous dulaglutide doses of 0.25, 0.5, or 0.75 mg (DU 0.25, DU 0.5, and DU 0.75, respectively) or placebo (n=36, 37, 35, and 37, respectively). The primary measure was change from baseline in glycated haemoglobin (HbA1c; %) at 12 weeks. Continuous variables were analysed using a mixed-effects model for repeated measures. Significant dose-dependent reductions in HbA1c were observed (least squares mean difference versus placebo [95% confidence interval]): DU 0.25=-0.72% (-0.95, -0.48), DU 0.5=-0.97% (-1.20, -0.73), and DU 0.75=-1.17% (-1.41, -0.93); p<0.001. Significant improvements in plasma glucose (PG), both fasting and average 7-point self-monitored blood glucose, were also observed with dulaglutide versus placebo (p<0.001). Dulaglutide was well-tolerated. Gastrointestinal adverse events (AEs) were more common in dulaglutide-treated patients, with nausea the most frequent (8 [5.5%]). Few dulaglutide-treated patients discontinued due to AEs (4 [3.7%]), and no serious AEs related to study medication occurred. Three patients (DU 0.5=1 and DU 0.75=2) reported asymptomatic hypoglycaemia (PG ≤70 mg/dL). The observed dose-dependent reduction in HbA1c and acceptable safety profile support further clinical development of dulaglutide for treatment of type 2 diabetes mellitus in Japan.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114 · cited 1×
“Additional measures included changes in 7-point self-monitored blood glucose (SMBG), fasting plasma glucose (PG; central laboratory), updated homeostasis model assessment of β-cell function (HOMA2-%B) and insulin sensitivity (HOMA2-%S) [9], body weight, and proportion of patients achieving HbA1c <7.”
MethodStandards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Pancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498
Long-Acting Glucagon-Like Peptide 1 Receptor Agonists
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s231 · Cited by 350
Li, L., Shen, J., Bala, M. M., Busse, J. W., Ebrahim, S., Vandvik, P. O., Rios, L. P., Malaga, G., Wong, E., Sohani, Z., et al. (2014) · BMJ · doi:10.1136/bmj.g2366 · Cited by 254
Alves, C., Batel-Marques, F., & Macedo, A. F. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.008 · Cited by 186
Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents
Gallwitz, B. (2011) · Drugs · doi:10.2165/11592810-000000000-00000 · Cited by 142
Barrington, P., Chien, J. Y., Showalter, H. D. H., Schneck, K., Cui, S., Tibaldi, F., Ellis, B., & Hardy, T. A. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01364.x · Cited by 120
Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I., & Mannucci, E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.01.010 · Cited by 106
Novel GLP-1 receptor agonists for diabetes
Garber, A. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.638282 · Cited by 69 · cited 1×
“Several GLP-1 receptor agonists have been developed or are in development for the treatment of type 2 diabetes mellitus [3-7].”
BackgroundPencek, R., Blickensderfer, A., Li, Y., Brunell, S. C., & Anderson, P. W. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2567 · Cited by 52 · cited 1×
“GLP-1 receptor agonists appear to be particularly effective in Asian and Japanese patients with type 2 diabetes mellitus, who tend to have a pathophysiology of insulin secretion impairment rather than insulin resistance and are inclined to be less obese compared to Western populations [17-20].”
Background
Research works printed but not linked: 18
- 1. Garber AJ (2011) Incretin therapy - present and future. Rev Diabet Stud 8: 307-322. · DOI
- 3. Combes J, Borot S, Mougel F, Penfornis A (2011) The potential role of glucagon-like peptide-1 or its analogues in enhancing glycaemic control in critically ill adult patients. Diabetes Obes Metab 13: 118-129. · DOI
- 4. Fineman MS, Cirincione BB, Maggs D, Diamant M (2012) GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab 14: 675-688. · DOI · Paper page
- 7. Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, et al. (2011) An overview of once-weekly glucagon-like peptide-1 receptor agonists - available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 13: 394-407. · DOI · Paper page
- 8. Glaesner W, Vick AM, Millican R, Ellis B, Tschang SH, et al. (2010) Engineering and characterization of the long-acting glucagonlike peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev 26: 287-296. · DOI · Paper page
- 13. Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, et al. (2012) Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med 29: 1260-1267. · DOI · Paper page
- 14. Barrington P, Chien JY, Tibaldi F, Showalter HD, Schneck K, et al. (2011) LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab 13: 434-438. · DOI · Paper page
- 15. Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, et al.; EGO Study Group (2011) The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab 13: 418-425. · DOI · Paper page
- 16. Seino Y, Rasmussen MF, Zdravkovic M, Kaku K (2008) Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 81: 161-168. · DOI
- 18. Yabe D, Seino Y (2011) Liraglutide in adults with type 2 diabetes: global perspective on safety, efficacy and patient preference. Clin Med Insights Endocrinol Diabetes 4: 47-62. · DOI
- 19. Fujimoto WY, Boyko EJ, Hayashi T, Kahn SE, Leonetti DL, et al. (2012) Risk factors for type 2 diabetes: lessons learned from Japanese Americans in Seattle. J Diabetes Investig 3: 212-224. · DOI
- 20. Hirose T, Kawamori R (2005) Diabetes in Japan. Curr Diab Rep 5: 226-229. · doi:10.1007/s11892-005-0013-4
- 21. Ratner RE, Rosenstock J, Boka G; DRI6012 Study Investigators (2010) Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med 27: 1024-1032. · DOI · Paper page
- 22. Kadowaki T, Namba M, Yamamura A, Sowa H, Wolka AM, et al. (2009) Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J 56: 415-424. · DOI · Paper page
- 23. Inagaki N, Atsumi Y, Oura T, Saito H, Imaoka T (2012) Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. Clin Ther 34: 1892-1908. · DOI
- 24. Ji L, Onishi Y, Ahn CW, Agarwal P, Chou CW, et al. (2013) Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with Type 2 diabetes mellitus. J Diabetes Investig 4: 53-61. · DOI · Paper page
- 25. Seino Y, Min KW, Niemoeller E, Takami A; EFC10887 GETGOAL-L Asia Study Investigators (2012) Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 14: 910-917. · DOI · Paper page
- 28. Funch D, Gydesen H, Tornøe K, Major-Pedersen A, Chan KA (2014) A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes Obes Metab 16: 273-275. · DOI · Paper page
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“33,78,104,114 Semaglutide .”
Jendle, J., Grunberger, G., Blevins, T., Giorgino, F., Hietpas, R. T., & Botros, F. T. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2810 · Cited by 158
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116
Fushimi, N., Shibuya, T., Yoshida, Y., Ito, S., Hachiya, H., & Mori, A. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13093 · Cited by 41
Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
Østergaard, L., Frandsen, C. S., & Madsbad, S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1121808 · Cited by 38
Metadata
- Authors
- Terauchi, Y., Satoi, Y., Takeuchi, M., & Imaoka, T.
- Venue
- Endocrine Journal
- Publisher
- Japan Endocrine Society
- Published
- 2014
- Volume
- 61
- Issue
- 10
- Pages
- 949-959
- ISSN
- 0918-8959 (ISSN-L)
- 1348-4540
- OpenAlex
- W2093375074
- Cited by
- 50
- References
- 11
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.